Vetigenics secures $6 million seed financing, sees meaningful clinical progress
Summary
Pet biotech establishes board of directors, looks ahead to therapies for autoimmune disease, obesity and allergy.PHILADELPHIA, Feb. 3, 2025 /PRNewswire/ -- Vetigenics, a clinical-stage animal health biotechnology company specializing in antibody therapeutics for pets, announces significant progress over the past year, including closing a $6 million seed round and advancing multiple clinical-stage programs.The investment sets the stage for accelerated growth and value creation for Vetigenics. "The funding underscores the confidence our investor partners have in our ability to achieve significant progress in a capital-efficient manner," says Adriann Sax, President, CEO and co-founder of Vetigenics. "The company has also established a board of directors made up of prominent industry leaders to guide its continued growth: , VMD, an EMR pioneer and tech innovator in the veterinary space , MBA, President, CEO and co- founder of Vetigenics.With a promising pipeline of clinical trials, new strategic partnerships, and an expanded team of experts, Vetigenics is poised to continue transforming pet health in 2025. Its proprietary CANIBODY technology unlocks faster, more cost-effective, and ethical solutions to develop superior antibodies proven effective in humans with cancer and chronic diseases but created specifically for pets. The companys innovative technology and pioneering expertise in antibody discovery and development are trusted by global animal health partners and the National Cancer Institute.